Triple-negative breast cancer (TNBC) constitutes around 15% of all breast cancer cases and is characterized by tumors that do not express estrogen receptor (ER), progesterone receptor (PR), and do not overexpress human epidermal growth factor receptor 2 (HER2) (10). This evidence concerns the gene ERBB2 and breast cancer.